The simultaneous impacts of global trade shifts, U.S. tax reforms, and changing drug pricing policies have prompted life ...

Strong IP keeps collaboration alive, allowing companies to attract capital, strike partnerships, and bring innovations to patients, according to legal experts at Ice Miller.

Tom Wells at 4C Associates, explores the future of biologistics, or how the packaging, storage, and logistics for biologics ...

Royalty-bearing license agreements are a cornerstone of commercialization in the life sciences and technology industries. Companies often use them to expand their business into new markets while ...

Since the start of his second term, President Trump has shown a clear commitment to improving access to medicines for American patients. In late September 2025, his Administration reaffirmed this ...

During a July episode of the Business of Biotech, Ebrahim Delpassand, M.D., founder, chairman, and CEO at RadioMedix, pointed out the importance of knowing, as a company, what you do best. It won’t be ...

Early-stage companies thrive on being nimble and running rather than walking. In times when funding is flowing and the IPO market is open, early partnering may be viewed with some skepticism out of ...

Roger Cone, Ph.D., a professor at the University of Michigan and the founder and chair of the scientific advisory board at Courage Therapeutics, has been thinking about the biological mechanics of ...

The Business of Biotech was taped in front of a live audience in Boston during the BIO conference last month, and we couldn’t have asked for a better guest to test out this new format. Amber Salzman, ...

Amid recent and proposed sweeping cuts to federal research funding, ranging from suspended federal funding to universities and research facilities to updated policy by the NIH (NIH) to reduce indirect ...

Patient safety is the top priority for regulators. While the industry and the public advocate for alternatives to animal testing, regulators require strong evidence that alternatives are equally safe ...

In this series, we will monitor emerging policies and priorities from the new Trump administration and its agencies that are expected to have particular effects on healthcare and life science-related ...